Local News

• Applied Biosystems reports fourth quarter financial results  Applied Biosystems reported net revenues of $609.0 million for the fourth quarter of fiscal 2008, an increase of 9% over the prior year quarter of $557.3 million. The net effect of foreign currency on net revenues was a favorable impact of approximately 5% compared to the prior year quarter.
  Applied Biosystems July 24, 2008  
• Invitrogen announces second quarter 2008 financial results  Invitrogen announced results for its second quarter ended June 30, 2008. Revenues for the second quarter were $368 million, an increase of 14.3 percent over the $322 million reported for the second quarter of 2007.
  Invitrogen Corporation July 24, 2008  
• Multithreaded supercomputer seeks software for data-intensive computing  Pacific Northwest National Laboratory and Cray Inc. lead a team that received $4 million to develop software for the newest breed of supercomputers to better tackle large networks of seemingly random data, applicable in internet security, power grid stability and complex biological networks.
  Pacific Northwest National Laboratory July 24, 2008  
• Cell Therapeutics raises $44.5 million from single institution  Cell Therapeutics announced that a single institutional investor has agreed to purchase, for $44.5 million, newly issued 18.33% Convertible Senior Notes and a warrant to purchase approximately 28.2 million shares of common stock with an exercise price of $0.79 per share.
  Cell Therapeutics, Inc. July 24, 2008  
• Dendreon expects interim data analysis for phase 3 PROVENGE IMPACT trial in October  Dendreon announced that it expects the Independent Data Monitoring Committee to review in October the interim analysis of overall survival relating to its Phase 3 IMPACT clinical trial of PROVENGE® the Company's investigational active cellular immunotherapy for treating advanced prostate cancer.
  Dendreon Corporation July 23, 2008  
• Cardiome Pharma announces $25 million preferred financing  Cardiome Pharma announced that it has entered into an agreement with CR Intrinsic Investments an investment fund managed by CR Intrinsic Investors, LLC, an affiliate of S.A.C. Capital Advisors, LLC to purchase Series A convertible preferred shares for gross proceeds of US$25 million.
  Cardiome Pharma Corp. July 23, 2008  
• Celera reports fourth quarter and fiscal 2008 results  Celera reported net revenues of $43.4 million for the fourth quarter of fiscal 2008, compared to $10.2 million in the prior year quarter. Celera reported a net loss of $96.8 million compared to a net loss of $8.0 million for the prior year quarter.
  Celera Corporation July 23, 2008  
• Genzyme reports strong second-quarter 2008 Growth  Genzyme reported that revenue increased 25 percent to approximately $1.171 billion from $933.4 million in last year’s second quarter. Net income was $69.6 million compared with $83.8 million in the second quarter a year ago.
  Genzyme Corporation July 23, 2008  
• CTI to meet with the FDA to discuss filing of a supplemental Biologics License Application  Cell Therapeutics announced that the Company has scheduled a meeting with the FDA in September to discuss the possibility of filing a supplemental Biologics License Application (sBLA) for use of Zevalin(R) ([90Y]-ibritumomab tiuxetan) as therapy after remission in non-Hodgkin's lymphoma.
  Cell Therapeutics, Inc. July 22, 2008  
• Ceapro appeals on litigation management focuses on building shareholder value  The remaining claims by Ceapro against the Saskatchewan Government Growth Fund and Saskatchewan Government Growth Fund Management Corporation were dismissed. The Board of Directors reviewed the Reasons for Decision with counsel and instructed that an appeal be initiated. This has now been done.
  Ceapro, Inc. July 22, 2008  

   (next 10 articles)